Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation

OBJECTIVES: Since the introduction of the German health care reform in January 2011, an early benefit assessment (EBA) is required for all new medicines. Pharmaceutical manufacturers have to submit a benefit dossier for evaluation by the Institute for Quality and Efficiency in Health Care (IQWiG). A...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruof, Jörg, Schwartz, Friedrich Wilhelm, Schulenburg, J.-Matthias, Dintsios, Charalabos-Markos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059963/
https://www.ncbi.nlm.nih.gov/pubmed/23771769
http://dx.doi.org/10.1007/s10198-013-0495-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059963/
https://www.ncbi.nlm.nih.gov/pubmed/23771769
http://dx.doi.org/10.1007/s10198-013-0495-y

Ejemplares similares